Articles Posted in the Articles Category
-
The “Green Revolution” Driving Investors to ecoTECH Energy
The need to cut usage of fossil fuels, so-call “brown energy,” is not exactly a new concept. Over the last three decades, U.S. governments have spent roughly $40 billion promoting the use of alternative energies. Today, the “green revolution” is beginning to hit its stride through not only a global social consciousness, but also through [...]
-
Rise in Money Laundering Fines Position Premier Alliance Group
Premier Alliance Group, Inc. (OTCBB: PIMO) is a business and technology consulting firm focused on providing solutions for Fortune 2000 companies in the areas of regulatory, compliance, business performance, transformation, and information management. Under the U.S. Bank Secrecy Act (BSA) and certain modifying provisions of the Patriot Act, banking institutions must report daily aggregate transactions [...]
-
Cellceutix Drug Slows Tumor Growth by 100% in Head and Neck Cancer
Cellceutix Corporation (OTCQB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, today provided additional research data on Kevetrin™, its p53 breakthrough anti-cancer compound. Kevetrin™ was studied as combination therapy with radiation to treat human head and neck cancer lines implanted in animals. While tumors treated with [...]
-
Access Pharma Aiming to Aid in Ovarian Cancer Fight
BusinessWeek.com ran a Health Day News article earlier this week reporting new research that shows ovarian cancer patients with the BRCA2 gene mutation are more likely to survive than those with the BRCA1 mutation or patients without either mutation. U.S. researchers analyzed 3,531 cases of epithelial ovarian cancer, comprised of: 1,178 patients with BRCA1 mutations [...]
-
Cellceutix to Present Kevetrin p53 Breakthrough at AACR Conference
Cellceutix Anti-Cancer Breakthrough Selected for Poster Presentation at American Association for Cancer Research (AACR) Cellceutix Corporation (OTCQB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat severe medical conditions including drug-resistant cancers, today announced that it will be presenting a poster titled “Kevetrin™, A Novel Small Molecule, Activates p53, Enhances [...]
-
The Cost of Diagnostics Versus the Cost of a Young Athlete’s Life
The title may have grabbed a reader’s attention and that was its purpose. All too often press releases that come from developmental companies are simply overlooked in the investment community as it doesn’t have a direct impact on today’s share price for the given company. Being an investor does not disassociate a person and their [...]
-
Cellceutix Drug Joins in Fight Against Leukemia
Cellceutix Discovers Drug Activates ‘Guardian Angel p53′ in Fight Against Leukemia Cellceutix Corporation (OTCQB: CTIX) today reported that its flagship cancer compound, Kevetrin™, has demonstrated potent anti-tumor activity in the treatment of leukemia cells in a hematopoietic xenograft tumor model. The activity, once again, is attributed to the reactivation of p53, the “Guardian Angel” protein, [...]
-
IC Places Signs New Agreement to Generate Additional Revenue
IC Places Continues Expansion and Monetizes Content If you ever looked at www.ICPlaces.com at its inception a few years ago, you will notice some dramatic changes as the site is now completely stuffed with information, videos and shows to entertain and educate its visitors. The World Wide Web has changed dramatically over the last six [...]
-
Cellceutix’s Kevetrin Proven Non-Genotoxic as Cancer Therapy
Cellceutix released news today on Kevetrin™ that continues to impress. This simple compound proved to reactivate p53, the “Guardian Angel of the Human Genome” as announced on Monday and today the news reports that Kevetrin is non-genotoxic. Genotoxic drugs (which are the majority of chemotherapy drugs used today) destroy the cancer cell, but do damage [...]
-
“Nice Shot” for Unilife (NASDAQ: UNIS) – The Scientist 2010
A well-articulated article in a January 2010 issue of “The Scientist” magazine, entitled “Nice Shot,” discusses a number of factors that have led to a dramatic wind shift favoring the vaccine segment of the pharmaceutical industry. The wind shift has caused the vaccine sector to go from unwanted orphan to beloved golden child. Increasing safety [...]
Partners
Partners
Copyright © 2013 Stock Market Video Charts.